{"id":1098,"date":"2022-06-14T07:08:58","date_gmt":"2022-06-14T07:08:58","guid":{"rendered":"https:\/\/digitalmecra.com\/?p=1098"},"modified":"2022-06-14T07:09:34","modified_gmt":"2022-06-14T07:09:34","slug":"meta-pharmaceuticals-otoimmun-ilaclar-icin-15-milyon-dolar-odenek-aldi","status":"publish","type":"post","link":"https:\/\/digitalmecra.com\/index.php\/2022\/06\/14\/meta-pharmaceuticals-otoimmun-ilaclar-icin-15-milyon-dolar-odenek-aldi\/","title":{"rendered":"Meta Pharmaceuticals Otoimm\u00fcn \u0130la\u00e7lar \u0130\u00e7in 15 milyon dolar \u00d6denek Ald\u0131"},"content":{"rendered":"

Art\u0131k Otoimm\u00fcn \u0130la\u00e7lar Var<\/h2>\n

Biyoteknoloji giri\u015fimi Meta Pharmaceuticals, ilk yat\u0131r\u0131m\u0131n\u0131 g\u00fcvence alt\u0131na al\u0131rken kendisine iddial\u0131 bir hedef koyuyor. Yapay zeka yard\u0131m\u0131yla otoimm\u00fcn hastal\u0131klar i\u00e7in tedaviler geli\u015ftirmek \u00fczere yola \u00e7\u0131kan Shenzhen merkezli \u015firket, tohum ve A \u00f6ncesi turlar\u0131ndan 15 milyon dolar toplad\u0131.<\/p>\n

K\u00fc\u00e7\u00fck molek\u00fcll\u00fc ila\u00e7 ke\u015ffine makine \u00f6\u011frenimi uygulayan \u015firketlerde yat\u0131r\u0131mc\u0131 ilgisi eksik de\u011fil. New York merkezli Immunai, insan ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin bir “atlas\u0131n\u0131” olu\u015fturmak i\u00e7in ge\u00e7en y\u0131l 215 milyon dolar toplad\u0131. Hong Kong’dan Insilico, CEO’nun \u201cbiyoteknoloji k\u0131\u015f\u0131\u201d olarak adland\u0131rd\u0131\u011f\u0131 s\u00fcre\u00e7ten ge\u00e7mesine ra\u011fmen k\u0131sa s\u00fcre \u00f6nce 60 milyon dolar kazand\u0131.<\/p>\n

2014’den Bu Yana \u00c7al\u0131\u015fmalar S\u00fcr\u00fcyor<\/h2>\n

Meta’n\u0131n teknolojisi, tarihsel olarak farkl\u0131 imm\u00fcnoloji ve metabolizma disiplinleri aras\u0131ndaki ili\u015fkiyi inceleyen, yeni ortaya \u00e7\u0131kan imm\u00fcno-metabolizma alan\u0131na girer. Bu yeni y\u00f6ntemle olu\u015fturulan ila\u00e7lar\u0131n, daha az yan etki ile ba\u011f\u0131\u015f\u0131kl\u0131k sistemini daha etkin bir \u015fekilde d\u00fczenledi\u011fi iddia ediliyor. Aslen g\u00fcneybat\u0131 \u00c7in’den olan Meta’n\u0131n kurucu orta\u011f\u0131 ve CEO’su Xu Ke, Weill Cornell Medicine’den mezun oldu ve ABD’deki en iyi kanser hastanelerinden biri olan Memorial Sloan Kettering Kanser Merkezi’nde ara\u015ft\u0131rma yapt\u0131.<\/p>\n

Meta sadece on ayl\u0131k ama bir end\u00fcstri g\u00f6revlisinin s\u0131rt\u0131ndan in\u015fa edildi. Bu, 2014 y\u0131l\u0131nda kurulan ve Tencent, Softbank Vision Fund ve Sequoia Capital China gibi \u015firketlerden bug\u00fcne kadar yakla\u015f\u0131k 800 milyon dolar fon toplayan yapay zeka destekli ila\u00e7 ke\u015ffi ve geli\u015ftirme ba\u015flang\u0131c\u0131 Xtalpi taraf\u0131ndan “kulu\u00e7kalanm\u0131\u015f” bir projedir.<\/p>\n

Meta’n\u0131n finansman turlar\u0131ndan yat\u0131r\u0131mc\u0131lar aras\u0131nda Xtalpi’nin kendisi, Forcefield Ventures, IMO Venture ve Tiantu Capital yer ald\u0131.<\/p>\n

Meta ve Xtalpi, yeni ila\u00e7 hedeflerini patentlere ve pazarlanabilir \u00fcr\u00fcnlere d\u00f6n\u00fc\u015ft\u00fcrmek i\u00e7in \u00e7al\u0131\u015farak birbirlerini a\u00e7\u0131k\u00e7a tamamlay\u0131c\u0131 roller oynarlar. Meta’n\u0131n \u00f6nerilen terap\u00f6tik hedefleri, ilk \u00f6nce ila\u00e7 ke\u015ffi veya bilgisayar destekli molek\u00fcler tasar\u0131ma at\u0131fta bulunan de novo ila\u00e7 tasar\u0131m\u0131 i\u00e7in XtalPi’ye gidecek. Bir Xtalpi s\u00f6zc\u00fcs\u00fc TechCrunch’a verdi\u011fi deme\u00e7te, bir klinik \u00f6ncesi aday belirlendikten sonra, Meta sonraki geli\u015ftirme, ara\u015ft\u0131rma ama\u00e7l\u0131 yeni ila\u00e7 (IND) dosyalama ve klinik denemeleri y\u00fcr\u00fctmek i\u00e7in devralabilir.<\/p>\n

Meta, AI \u00f6zellikli hedef ke\u015fif platformunda binlerce proteaz\u0131 elendikten sonra bir dizi metabolik proteaz hedefi ke\u015ffetti\u011fini iddia ediyor.<\/p>\n

\"\"<\/p>\n

Medikal Teknolojinin Gelece\u011fi<\/h2>\n

Xu, TechCrunch’a yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, giri\u015fimin hedef ke\u015fif teknolojisinin ilk e\u011fitimi i\u00e7in halka a\u00e7\u0131k verileri kulland\u0131\u011f\u0131n\u0131 ve yolun a\u015fa\u011f\u0131s\u0131ndaki \u00c7in’deki hastanelerle i\u015fbirli\u011fi i\u00e7inde hastalardan ve sa\u011fl\u0131kl\u0131 ba\u011f\u0131\u015f\u00e7\u0131lardan \u00f6rnekler ve omik verileri toplamay\u0131 planlad\u0131\u011f\u0131n\u0131 s\u00f6yledi.<\/p>\n

Rekabet hakk\u0131nda soru soruldu\u011funda Xu, “Bilgi hatt\u0131m\u0131z \u00e7ok \u00e7e\u015fitli otoimm\u00fcn sorunlar\u0131, kanseri ve ya\u015fa ba\u011fl\u0131 hastal\u0131klar\u0131 tedavi etmek i\u00e7in kullan\u0131lma potansiyeline sahip” dedi. “\u00d6zellikleri hen\u00fcz payla\u015fmak veya kendimizi bir veya iki mevcut ila\u00e7 ve endikasyonla s\u0131n\u0131rlamak i\u00e7in hen\u00fcz \u00e7ok erken.”<\/p>\n

Di\u011fer \u00c7al\u0131\u015fmalar<\/h2>\n

Merkezi, Shenzhen’de Hong Kong s\u0131n\u0131r\u0131ndaki bir inovasyon serbest ticaret b\u00f6lgesinde bulunan Meta, ila\u00e7lar\u0131n\u0131 k\u00fcresel olarak pazarlamay\u0131 planl\u0131yor. B\u00f6lge, emekleme d\u00f6neminde, Shenzhen ve Hong Kong aras\u0131ndaki teknolojik i\u015fbirli\u011fini te\u015fvik etmek i\u00e7in h\u00fck\u00fcmet liderli\u011findeki bir\u00e7ok giri\u015fimden biridir. Giri\u015fimlere destek \u00e7e\u015fitli \u015fekillerde gelir ve Meta’n\u0131n durumunda, ithal edilen laboratuvar ekipmanlar\u0131nda vergi muafiyeti anlam\u0131na gelir. B\u00f6lge ayn\u0131 zamanda Xtalpi’ye ve \u00c7in’in en b\u00fcy\u00fck otonom s\u00fcr\u00fc\u015f giri\u015fimlerinden biri olan Deeproute.ai’ye de ev sahipli\u011fi yap\u0131yor.<\/p>\n

 <\/p>\n

Kaynak<\/a><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Yapay zeka yard\u0131m\u0131yla otoimm\u00fcn hastal\u0131klar i\u00e7in tedaviler geli\u015ftirmek \u00fczere yola \u00e7\u0131kan Shenzhen merkezli \u015firket, tohum ve A \u00f6ncesi turlar\u0131ndan 15 milyon dolar toplad\u0131.<\/p>\n","protected":false},"author":6,"featured_media":1099,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,14],"tags":[305,575],"class_list":["post-1098","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dunya","category-teknoloji","tag-haber","tag-teknoloji"],"views":1027,"_links":{"self":[{"href":"https:\/\/digitalmecra.com\/index.php\/wp-json\/wp\/v2\/posts\/1098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/digitalmecra.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/digitalmecra.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/digitalmecra.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/digitalmecra.com\/index.php\/wp-json\/wp\/v2\/comments?post=1098"}],"version-history":[{"count":2,"href":"https:\/\/digitalmecra.com\/index.php\/wp-json\/wp\/v2\/posts\/1098\/revisions"}],"predecessor-version":[{"id":1102,"href":"https:\/\/digitalmecra.com\/index.php\/wp-json\/wp\/v2\/posts\/1098\/revisions\/1102"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/digitalmecra.com\/index.php\/wp-json\/wp\/v2\/media\/1099"}],"wp:attachment":[{"href":"https:\/\/digitalmecra.com\/index.php\/wp-json\/wp\/v2\/media?parent=1098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/digitalmecra.com\/index.php\/wp-json\/wp\/v2\/categories?post=1098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/digitalmecra.com\/index.php\/wp-json\/wp\/v2\/tags?post=1098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}